Previsioni
Il prezzo obiettivo medio degli analisti è 27,80 € (+309,43%). La mediana è 27,80 € (+309,43%).
| Acquista |
12 |
| Mantieni |
5 |
| Vendi |
4 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Arcturus Therapeutics presents pipeline at Cantor conference; pivotal data expected soon
Arcturus Therapeutics presented three core programs at the Cantor Global Healthcare Conference: ARCT-810 for OTC deficiency, an inhaled mRNA program for cystic fibrosis (CF), and a self-amplifying mRNA platform with commercial vaccine success. Near-term catalysts include the Phase II readout for ARCT-810 expected later this month, FDA feedback, and a fourth-quarter decision on whether to continue the CF program — a move that could trigger funding from Thermo Fisher. Management highlights technological advantages (biodegradable LNPs, improved mRNA purification, a tailored nebulizer) but still sees risks around efficacy, safety and competition. » Altro su de.investing.com
Arcturus Therapeutics sees 2026 as a turning point with two near-term catalysts
At the Citigroup conference, Arcturus Therapeutics announced two near-term catalysts: Phase II data on OTC deficiency in September and a go/no-go decision on initiating Phase III for cystic fibrosis in the fourth quarter. The inhaled mRNA platform was presented as differentiated after safety and tolerability issues were addressed. Thermo Fisher has committed up to $40 million to non-dilutively support the Phase III cystic fibrosis development in exchange for exclusive manufacturing rights. The vaccine business provides non-dilutive revenue to fund the therapeutic pipeline; substantial CF data are expected in early 2025. » Altro su de.investing.com
Arcturus Therapeutics jumps after management signal and conference announcements
Arcturus Therapeutics’ stock rose intraday by about 10–13% after management announced participation in five major investor conferences in September, viewed as a vote of confidence in the pipeline. Key clinical milestones for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) are approaching. Analyst support, better-than-expected quarterly results, more than $191 million in cash and a strategic manufacturing agreement with Thermo Fisher bolster the funding outlook through 2028 and the credibility for a potential phase 3 study. The rally occurred despite a weaker broader market and appears to be company-specific. » Altro su de.investing.com
Arcturus highlights strong liquidity and upcoming clinical catalysts
Arcturus has more than $200 million in liquidity, giving it a funding runway into 2028 to support development of its programs. The company expects a Q4 2024 decision on advancing ARCT-032 (inhaled mRNA for cystic fibrosis) into phase III and anticipates data and regulatory guidance for ARCT-810 (OTC deficiency) before Sept. 30, 2024. The vaccine business, including KOSTAIVE (approved in 32 countries), has been returned to 100% strategic control and is intended to help fund the therapeutics pipeline. Arcturus is evaluating partnerships and has outlined a possible $40 million support from Thermo Fisher tied to a phase III decision. » Altro su de.investing.com
Arcturus Therapeutics reduces quarterly loss more than expected despite 89% revenue drop
Arcturus reported an adjusted loss of $0.84 per share in Q2 versus a consensus expectation of $1.05, beating estimates by 20%. Revenue fell to $2.96 million, a decline of 89.4% year‑on‑year after the end of the collaboration with CSL Seqirus. Cash and equivalents amounted to $191.5 million, securing a liquidity runway of more than 2.5 years. The company cut R&D spending, is advancing cystic fibrosis (ARCT‑032) and OTCD (ARCT‑810) programs, and expects Phase II/III decisions and data in the second half of 2026. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheNel 2012, Arcturus Therapeutics ha già distribuito 2,66 € di dividendi. L'ultimo pagamento è avvenuto a dicembre 2012.
Dati finanziari
Nell'ultimo trimestre, Arcturus Therapeutics ha registrato ricavi pari a 16,15 Mln € e un utile netto di -6,55 Mln €
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 16,15 Mln | 10,53% |
| Utile lordo | 16,15 Mln | 37,28% |
| Utile netto | -6,55 Mln | 42,88% |
| EBITDA | -6,55 Mln | 39,45% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 211,19 Mln € |
Numero di azioni | 28,82 Mln |
Massimo/minimo a 52 settimane | 16,37 € - 5,01 € |
| Dividendi | No |
Beta | 2,61 |
Rapporto P/E | -2,59 |
Rapporto PEG | 0,10 |
Rapporto P/B | 1,36 |
Rapporto P/S | 9,29 |
Profilo aziendale
Arcturus Therapeutics Holdings Inc., un'azienda di farmaci a base di RNA, si concentra nello sviluppo di vaccini per malattie infettive, nonché di terapie per malattie rare del fegato e dell'apparato respiratorio negli Stati Uniti. I programmi di sviluppo dell'azienda comprendono il programma LUNAR-OTC per il deficit di ornitina transcarbamilasi (OTC); e il programma LUNAR-CF per la malattia polmonare da fibrosi cistica causata da mutazioni nel gene del regolatore di conduttanza transmembrana della fibrosi cistica (CFTR), oltre ai programmi vaccinali LUNAR-COV19 e LUNAR-FLU. Ha partnership di collaborazione con Vinbiocare Biotechnology Joint Stock Company per la produzione di vaccini contro la COVID-19; Janssen Pharmaceuticals, Inc. per lo sviluppo di candidati terapeutici a base di acidi nucleici per il trattamento del virus dell'epatite B; Ultragenyx Pharmaceutical, Inc. per lo sviluppo di candidati terapeutici a mRNA per bersagli di malattie rare; CureVac AG per lo sviluppo di candidati terapeutici e vaccinali a mRNA per varie indicazioni; Singapore Economic Development Board e Duke-NUS Medical School per lo sviluppo del vaccino LUNAR-COV19; e Millennium Pharmaceuticals, Inc. per la scoperta di farmaci a base di siRNA per il trattamento della steatoepatite non alcolica. La società è stata fondata nel 2013 e ha sede a San Diego, California.
| Nome | Arcturus Therapeutics |
| CEO | Joseph E. Payne |
| Sede centrale | San Diego,
ca Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 22/05/2013 |
| Dipendenti | 109 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | ARCT |